What's breaking now, across thousands of outlets.
Dr. Danish Nagda, a shareholder in the developer, told Fortune it was "incredibly exciting ... maybe half a decade away from the post-cancer era."
We haven't written up this one. Fortune has the full story — the link below goes straight to it.
In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as those who only received chemotherapy.
Click in for more news from The Hill {beacon} Healthcare Healthcare The Big Story Kennedy feuds with Shapiro over vaccines An online row between Health and Human Services Secretary Robert F.
Breast cancer is often classified as either estrogen receptor-positive (hormone-sensitive) or not. However, a new study from Karolinska Institutet suggests that this simplified classification may…
Norah O'Donnell tells Laurie Cox why she started studying the gut microbiome and what she eats to keep hers happy.
Meta agreed to pay up to $17 billion in a settlement, putting to rest a trial where dozens of states accused it of deliberately endangering children through their platforms.
Laura Syron: Addressing food security will lower Canadians’ risk of developing type 2 and gestational diabetes, improve outcomes for those living with diabetes, and ultimately decrease health-care…
